Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

 

May 2013

 

Clinical Trials, Cohort Studies, Pilot Studies                              1 - 6                

Basic and Applied Science, Pre-Clinical Studies              6 - 10

HIV/HCV Coinfection                                                              10 - 12

Epidemiology, Diagnostics & Miscellaneous Works                12 - 16

Liver Cancer                                                                              16 - 22

 

Clinical Trials, Cohort Studies, Pilot Studies

 

High proportion of hepatitis C virus in community Asian American patients with non-liver-related complaints. Kin KC, Lin B, Ha NB, et al. J Clin Gastroenterol. 2013 Apr;47(4):367-71. doi: 10.1097/MCG.0b013e3182688b3e.

http://www.ncbi.nlm.nih.gov/pubmed/23090039

 

Management of the Extrahepatic Symptoms of Chronic Hepatitis C: Feasibility of a Randomized Controlled Trial of Exercise. McKenna O, Cunningham C, Gissane C, Blake C. Am J Phys Med Rehabil. 2013 Apr 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23552336

 

Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Zeuzem S, Asselah T, Angus P, et al. Antivir Ther. 2013 Apr 4. doi: 10.3851/IMP2567. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23558093

 

Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. Huang CF, Yu ML, et al. J Clin Virol. 2013 Apr;56(4):293-8. doi: 10.1016/j.jcv.2012.11.015.

http://www.ncbi.nlm.nih.gov/pubmed/23246359

 

Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. Huang CF, Yeh ML, Hsieh MH, et al. J Gastroenterol Hepatol. 2013 Apr 5. doi: 10.1111/jgh.12211. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23560893

 

Alterations in NK Cell Phenotype in Relation to Liver Steatosis in Children with Chronic Hepatitis C. Mania A, Kaczmarek M, Kemnitz P, et al. Inflammation. 2013 Apr 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23558709

 

 

Serotonin and interleukin-6: The role of genetic polymorphisms in IFN-induced neuro-psychiatric symptoms. Udina M, Moreno-España J, Navinés R, et al.

http://www.ncbi.nlm.nih.gov/pubmed/23571152

 

Virus C Hepatitis and Type 2 Diabetes: A Cohort Study in Southern Italy. Montenegro L, De Michina A, Misciagna G, Guerra V, Di Leo A. Am J Gastroenterol. 2013 Apr 9. doi: 10.1038/ajg.2013.90. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23567360

 

Hepatitis C virus transmission during colonoscopy evidenced by phylogenetic analysis.

Saludes V, Esteve M, Casas I, Ausina V, Martró E. J Clin Virol. 2013 Apr 5. pii: S1386-6532(13)00090-5. doi: 10.1016/j.jcv.2013.03.007. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23567025

 

Basic and Applied Science, Pre-Clinical Studies

 

Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients. Angulo J, Pino K, Pavez C, et al. J Viral Hepat. 2013 Apr;20(4):263-72. doi: 10.1111/jvh.12076.

http://www.ncbi.nlm.nih.gov/pubmed/23490371

 

Genome-wide analysis of host mRNA translation during hepatitis C virus infection.

Colman H, Le Berre-Scoul C, Hernandez C, et al. J Virol. 2013 Apr 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23552407

 

The anti-idiotypic antibody 1F7 stimulates monocyte interleukin-10 production and induces endotoxin tolerance. Davtyan TK, Poghosyan DA, Sukiasyan AG, Grant MD. J Inflamm (Lond). 2013 Apr 5;10(1):14. doi: 10.1186/1476-9255-10-14.

http://www.ncbi.nlm.nih.gov/pubmed/23561395

 

Mutual Antagonism between Circadian Protein Period 2 and Hepatitis C Virus Replication in Hepatocytes. Benegiamo G, Mazzoccoli G, Cappello F, et al. PLoS One. 2013 Apr 8;8(4):e60527. doi: 10.1371/journal.pone.0060527. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23593233

 

Association of TIMP-1 and TIMP-2 Gene Polymorphisms with Progression of Liver Fibrosis in Patients with Type C Chronic Liver Disease. Ikebuchi Y, Ishida C, Okamoto K, Murawaki Y. Biochem Genet. 2013 Apr 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23563628

 

Evaluation of Coumarin and Neoflavone Derivatives as HCV NS5B Polymerase Inhibitors.

Nichols DB, Leão RA, Basu A, et al. Chem Biol Drug Des. 2013 May;81(5):607-14. doi: 10.1111/cbdd.12105. Epub 2013 Apr 4.

http://www.ncbi.nlm.nih.gov/pubmed/23311976

 

Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Everhart JE, Wright EC. Hepatology. 2013 May;57(5):1725-33. doi: 10.1002/hep.26203. Epub 2013 Apr 5.

http://www.ncbi.nlm.nih.gov/pubmed/23258530

 

Hepatitis C Virus Core Protein Down-Regulates p21(Waf1/Cip1) and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.

Shiu TY, Huang SM, Shih YL, et al. PLoS One. 2013;8(4):e61089. doi: 10.1371/ journal.pone.0061089. Epub 2013 Apr 8.

http://www.ncbi.nlm.nih.gov/pubmed/23577194

 

Discovery of cellular proteins required for the early steps of HCV infection using integrative genomics. Park JH, Park S, Yang JS, Kwon OS, Kim S, Jang SK. PLoS One. 2013 Apr 12;8(4):e60333. doi: 10.1371/journal.pone.0060333. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23593195

 

HIV/HCV Coinfection

 

Neutropenia During Therapy with Peginterferon and Ribavirin in HIV-Infected Subjects with Chronic Hepatitis C and the Risk of Infections. Serrano-Villar S, Quereda C, Moreno A, et al. Clin Infect Dis. 2013 Apr 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23575196

 

HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin. Feijoo J, Eirea M, Limeres J, Abeleira M, Ramos I, Ocampo A, Diz P. Oral Dis. 2013 Apr 12. doi: 10.1111/odi.12116. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23607445

 

Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? Rockstroh JK, Peters L, Grint D, et al. J Hepatol. 2013 Apr 10. pii: S0168-8278(13)00220-1. doi: 10.1016/j.jhep.2013.04.005. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23583272

 

The changing pattern of glomerular disease in HIV and Hepatitis C co-infected patients in the era of HAART. Mohan S, Herlitz LC, Tan J, et al. Clin Nephrol. 2013 Apr;79(4):285-91. doi: 10.5414/CN107774.

http://www.ncbi.nlm.nih.gov/pubmed/23320974

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Between harm reduction, loss and wellness: on the occupational hazards of work. Shepard BC. Harm Reduct J. 2013 Apr 1;10(1):5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23548032

 

A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care.

McGowan CE, Monis A, Bacon BR, et al. Hepatology. 2013 Apr;57(4):1325-32. doi: 10.1002/hep.26246.

http://www.ncbi.nlm.nih.gov/pubmed/23315914

 

The Association Between Law Enforcement Encounters and Syringe Sharing Among IDUs on Skid Row: A Mixed Methods Analysis.

Wagner KD, Simon-Freeman R, Bluthenthal RN. AIDS Behav. 2013 Apr 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23620243

 

Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. de Lédinghen V, Vergniol J, Barthe C, et al. Aliment Pharmacol Ther. 2013 May;37(10):979-88. doi: 10.1111/apt.12307. Epub 2013 Apr 5.

http://www.ncbi.nlm.nih.gov/pubmed/23557139

 

Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interactions.

Kiang TK, Wilby KJ, Ensom MH. Clin Pharmacokinet. 2013 Apr 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23553423

 

Gender medicine: a task for the third millennium. Baggio G, Corsini A, Floreani A, Giannini S, Zagonel V. Clin Chem Lab Med. 2013 Apr 1;51(4):713-27. doi: 10.1515/cclm-2012-0849.

http://www.ncbi.nlm.nih.gov/pubmed/23515103

 

Emerging Therapeutic Targets for Hepatitis C Virus Infection. Jesudian AB, de Jong YP, Jacobson IM. Clin Gastroenterol Hepatol. 2013 Apr 11. pii: S1542-3565(13)00457-6. doi: 10.1016/j.cgh.2013.04.003. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23583900

 

Liver Cancer

 

Antiproliferative effects of sorafenib and pegylated IFN α2b on human liver cancer cells in vitro and in vivo. Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, Yano H. Int J Oncol. 2013 Jun;42(6):1897-903. doi: 10.3892/ijo.2013.1904. Epub 2013 Apr 16.

http://www.ncbi.nlm.nih.gov/pubmed/23588838

 

Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM. Genomics. 2013 Apr 11. pii: S0888-7543(13)00063-3. doi: 10.1016/j.ygeno.2013.04.001. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23583669

 

Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. Costantini S, Capone F, Maio P, Guerriero E, Colonna G, Izzo F, Castello G. Oncol Rep. 2013 Jun;29(6):2163-8. doi: 10.3892/or.2013.2378. Epub 2013 Apr 3.

http://www.ncbi.nlm.nih.gov/pubmed/23564159

 

 

 

Identification of a Functional Variant in the MICA Promoter Which Regulates MICA Expression and Increases HCV-Related Hepatocellular Carcinoma Risk. Lo PH, Urabe Y, Kumar V, et al. PLoS One. 2013 Apr 11;8(4):e61279. doi: 10.1371/journal.pone.0061279. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23593449

 

α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Asahina Y, Tsuchiya K, Nishimura T, et al. Hepatology. 2013 Apr 8. doi: 10.1002/hep.26442. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23564522

 

Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. Fushiya N, Takagi I, Nishino H, Akizuki S, Ohnishi A. Anticancer Drugs. 2013 Apr 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23571497

 

Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Lee D, Chung YH, Kim JA, et al. Cancer. 2013 Apr 5. doi: 10.1002/cncr.28082. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23564564

 

A Hepatocellular Carcinoma 5-Gene Score Associated with Survival of Patients Following Liver Resection. Nault JC, de Reyniès A, Villanueva A, et al. Gastroenterology. 2013 Apr 5. pii: S0016-5085(13)00494-0. doi: 10.1053/j.gastro.2013.03.051. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23567350

 

Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials.

Sun P, Yang X, He RQ, Hu QG, Song ZF, Xiong J, Zheng QC. Hepatol Res. 2013 Apr 2. doi: 10.1111/hepr.12115. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23607290

 

The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. Nishikawa H, Osaki Y, Iguchi E, et al. J Clin Gastroenterol. 2013 Apr;47(4):359-66. doi: 10.1097/MCG.0b013e31826be9ad.

http://www.ncbi.nlm.nih.gov/pubmed/23090049

 

Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. Bujold A, Massey CA, Kim JJ, et al. J Clin Oncol. 2013 Apr 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23547075